HOME >> BIOLOGY >> NEWS
Alcoholism risk linked to gene involved in brain chemistry

Indianapolis -- A research team headed by Indiana University School of Medicine scientists has identified a gene that is strongly linked to an individual's risk of developing alcoholism.

The gene identified, GABRA2, is one of several genes that produce parts of the receptor for the brain's primary inhibitory neurotransmitter, GABA. GABA is a chemical messenger that carries information between nerve cells; when GABA binds to the GABA-receptors on a nerve cell, it inhibits the firing of that cell. GABA is known to be involved with some of the body's responses to alcohol consumption, such as loss of physical coordination, effect on mood, and alcohol withdrawal symptoms.

Alcoholism, which affects nearly 14 million Americans and can cause many social and health problems costing society an estimated $185 billion annually, is what scientists call a "complex" disease, meaning that many genes as well as environmental factors play a role in whether a person develops the disease.

While there is not one single "gene that causes alcoholism" the statistical link between this gene and the risk for alcoholism is powerful, said Howard J. Edenberg, Ph.D., Chancellor's Professor at the IU School of Medicine. Edenberg was the lead researcher for the study, which appears in the April issue of the American Journal of Human Genetics.

"Statistically, this is very strong evidence that this gene affects the risk of alcoholism," said Edenberg, professor of biochemistry and molecular biology and of medical and molecular genetics.

As researchers identify genes and brain signaling pathways associated with alcoholism -- and learn how they vary from one person to another -- opportunities should arise for development of more precisely targeted drugs, and for individualized approaches to prevent and treat alcoholism, Edenberg said.

"We may be able to target therapies and preventative treatments based on individual characteristics," he said. The res
'"/>

Contact: Eric Schoch
eschoch@iupui.edu
317-274-7722
Indiana University
15-Apr-2004


Page: 1 2

Related biology news :

1. UCSF Research Team Looking For Volunteers For Nationwide Study On Family Traits And Alcoholism
2. Genetic mutations linked to the practice of burning coal in homes in China
3. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
4. Protein involved in childhood disorder linked to cancer
5. Mouse study shows NPAS3 and NPAS1 genes may be linked to psychosis
6. Gene linked to cleft lip and palate identified
7. Schizophrenia gene variant linked to risk traits
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Excess levels of nitrogen, phosphorus linked to deformed frogs
10. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
11. LBP-1a gene mutation linked to disruption of normal fetal development

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Alcoholism risk linked gene involved brain chemistry

(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new ... The tour and course will be given every Wednesday at 6pm to local interested ... members are welcome to attend with their veterinarian as well. Participants will be able ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
Cached News: